Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

Source:http://linkedlifedata.com/resource/pubmed/id/17010609

Download in:

View as

General Info

PMID
17010609